Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Given Average Rating of “Hold” by Analysts

Shares of Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) have been assigned an average rating of “Hold” from the eleven brokerages that are covering the firm, MarketBeat reports. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating and five have assigned a buy rating to the company. The average 12 month price objective among analysts that have issued ratings on the stock in the last year is $10.28.

MRVI has been the subject of several analyst reports. Robert W. Baird dropped their price target on shares of Maravai LifeSciences from $10.00 to $9.00 and set an “outperform” rating for the company in a research note on Friday, November 8th. Wolfe Research initiated coverage on Maravai LifeSciences in a research report on Thursday, November 14th. They issued a “peer perform” rating for the company. The Goldman Sachs Group downgraded Maravai LifeSciences from a “neutral” rating to a “sell” rating and reduced their target price for the company from $7.00 to $4.25 in a research report on Thursday, December 5th. Royal Bank of Canada decreased their price target on Maravai LifeSciences from $17.00 to $13.00 and set an “outperform” rating on the stock in a research note on Friday, November 8th. Finally, William Blair reissued a “market perform” rating on shares of Maravai LifeSciences in a research report on Friday, November 8th.

Maravai LifeSciences Trading Down 1.4 %

MRVI opened at $4.24 on Wednesday. The firm has a market capitalization of $1.07 billion, a price-to-earnings ratio of -2.59 and a beta of -0.08. The company’s 50 day simple moving average is $5.28 and its two-hundred day simple moving average is $6.93. Maravai LifeSciences has a 1-year low of $4.16 and a 1-year high of $11.56. The company has a debt-to-equity ratio of 0.89, a current ratio of 10.74 and a quick ratio of 9.94.

Insider Transactions at Maravai LifeSciences

In other Maravai LifeSciences news, General Counsel Kurt Oreshack sold 25,000 shares of the firm’s stock in a transaction dated Friday, January 31st. The shares were sold at an average price of $5.03, for a total transaction of $125,750.00. Following the completion of the transaction, the general counsel now directly owns 167,618 shares in the company, valued at approximately $843,118.54. This trade represents a 12.98 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Corporate insiders own 0.63% of the company’s stock.

Institutional Trading of Maravai LifeSciences

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in MRVI. Performa Ltd US LLC lifted its stake in shares of Maravai LifeSciences by 614.3% during the fourth quarter. Performa Ltd US LLC now owns 5,000 shares of the company’s stock valued at $27,000 after buying an additional 4,300 shares during the period. FNY Investment Advisers LLC lifted its stake in shares of Maravai LifeSciences by 600.0% during the 4th quarter. FNY Investment Advisers LLC now owns 7,000 shares of the company’s stock worth $38,000 after purchasing an additional 6,000 shares during the period. Venturi Wealth Management LLC acquired a new stake in shares of Maravai LifeSciences during the third quarter worth $47,000. Farther Finance Advisors LLC grew its position in shares of Maravai LifeSciences by 3,541.4% in the fourth quarter. Farther Finance Advisors LLC now owns 10,196 shares of the company’s stock valued at $56,000 after purchasing an additional 9,916 shares during the period. Finally, Cibc World Markets Corp purchased a new stake in shares of Maravai LifeSciences in the fourth quarter valued at $56,000. Hedge funds and other institutional investors own 50.25% of the company’s stock.

About Maravai LifeSciences

Maravai LifeSciences Holdings, Inc, a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company’s products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species.